NeOnc Technologies Appoints First Abu Dhabi Bank Executive Ali Alabedin to Board
NeOnc Technologies Holdings, Inc. (NTHI) appointed Ali Alabedin to its board of directors, effective October 9, 2026. Alabedin currently serves as the Head of Islamic Banking Group at First Abu Dhabi Bank. He succeeds Dr. Steven L. Giannotta, who stepped down from the board and will continue to serve on the company's Scientific Advisory Board.
The appointment brings senior banking and governance experience to NeOnc as the clinical-stage biopharmaceutical firm expands its international presence. The company focuses on developing chemotherapy agents designed to penetrate the blood-brain barrier for central nervous system cancers.
Investors will monitor NeOnc's upcoming clinical milestones in the United Arab Emirates. Health authorities in Abu Dhabi granted Investigational New Drug authorization for the company's candidate NEO212, clearing the path toward Phase 2 clinical trials subject to final ethics approvals and pre-enrollment conditions.
Key points
- Ali Alabedin joined the board of directors at NeOnc Technologies Holdings, Inc. on October 9, 2026.
- Alabedin brings over 30 years of experience, serving as Head of Islamic Banking Group at First Abu Dhabi Bank.
- The board addition supports NeOnc's governance and Phase 2 trial plans for candidate NEO212 in Abu Dhabi.
- Dr. Steven L. Giannotta stepped down from the board to transition to NeOnc's Scientific Advisory Board.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who is Ali Alabedin and what is his role at NeOnc Technologies?
Ali Alabedin is the Head of Islamic Banking Group at First Abu Dhabi Bank. He joined NeOnc Technologies Holdings, Inc. as a board member on October 9, 2026, to support financial governance and expansion in Abu Dhabi.
What clinical developments is NeOnc Technologies pursuing in Abu Dhabi?
NeOnc received IND authorization from health authorities in Abu Dhabi for its brain cancer drug candidate NEO212, supporting plans for Phase 2 trials subject to required ethics approvals and pre-enrollment conditions.
Who did Ali Alabedin replace on NeOnc's board of directors?
Ali Alabedin succeeded Dr. Steven L. Giannotta on the board. Dr. Giannotta stepped down from his board role to continue serving on NeOnc's Scientific Advisory Board.